GlassScriptPhysician profile
Sandra N Holzhauer-Feeney
NPI 1992773055
$2,400.95
in general payments reported to CMS, 2019-2025
30 companies · $337 in 2025
The $337 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $159 · 2021: $336 · 2022: $596 · 2023: $437 · 2024: $276 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,050.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $632.53 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $298.85 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $196.70 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $171.66 | 2022 | |
| Amgen INC. | $123.72 | 2019-2025 | Evenity, Otezla, Repatha |
| Pfizer INC. | $111.44 | 2019-2024 | |
| Biohaven Pharmaceuticals, INC. | $98.80 | 2021 | |
| Novo Nordisk INC | $64.32 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $56.45 | 2021-2025 | Eliquis |
| Ucb, INC. | $54.23 | 2019-2023 | Nayzilam |
| Exact Sciences Corporation | $50.74 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $42.15 | 2020 | |
| Pulmonx Corporation | $41.72 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Vanda Pharmaceuticals INC. | $40.37 | 2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $39.71 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $38.65 | 2019-2021 | |
| Glaxosmithkline, LLC. | $35.08 | 2020-2025 | Arexvy, Shingrix, Bexsero |
| Axsome Therapeutics, INC. | $34.78 | 2024 | Auvelity |
| Merck Sharp & Dohme LLC | $34.57 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.04 | 2025 | Caplyta |
| Medtronic USA, INC. | $30.07 | 2019 | |
| Novartis Pharmaceuticals Corporation | $26.69 | 2023 | |
| Jazz Pharmaceuticals INC. | $20.95 | 2021 | |
| Sunovion Pharmaceuticals INC. | $19.39 | 2020 | |
| Dynavax Technologies Corporation | $19.29 | 2019 | |
| Eisai INC. | $19.20 | 2020 | |
| Xeris Pharmaceuticals, INC. | $17.67 | 2023 | Gvoke Hypopen |
| Medtronic Minimed, INC. | $16.96 | 2020 | |
| Sanofi Pasteur INC. | $16.68 | 2023 | |
| Medtronic, INC. | $13.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Holzhauer-Feeney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.